Objective The aim was to assess expression of Annexin A1
(ANXA1) on malignant myeloid blast cells and its correlation
with clinical outcome, overall survival (OS), and other
prognostic factors among adult Egyptian patients with acute
myeloid leukemia (AML).
Patients and methods A total of 60 patients with de novo
AML were treated and followed up in Ain Shams University
Hospitals, Hematology Unit and compared with 20 agematched
and sex-matched normal healthy controls.
Expression of ANXA1 was detected by flow cytometry in bone
marrow samples.
Results Patients with AML had significant higher mean
ANXA1 expression than mean ANXA1 expression in control
at D0.
The mean ANXA1 level in the favorable cytogenetics group
was significantly higher than the mean ANXA1 level in the
unfavorable cytogenetics group. ANXA1 was positive in
76.7% patients with AML and negative in 23.3% patients
with AML.
There was a significant difference between ANXA1-positive
group and ANXA1-negative group of patients with AML
regarding different outcomes. In ANXA1-positive group,
52.2% of patients with AML achieved complete remission
(CR), whereas in ANXA1-negative group, 14.3% of patients
with AML achieved CR. Highest mean ANXA1 expression
was in the group of patients who had CR. High ANXA1
expression was associated with longer OS.
Conclusion ANXA1 is significantly expressed in Egyptian
patients with de novo AML, and its expression associated with
favorable prognostic effect on clinical outcome and longer
OS.